



Hosts the

11th International Symposium on Translational Research in Oncology

**Chairs: Prof John Crown (Dublin)
Prof Robert Kerbel (Toronto)
Prof Mario Sznol (Yale)**

**Thursday, Friday & Saturday
September 27th, 28th & 29th 2018**

Herbert Park Hotel, Ballsbridge, Dublin 4

40 Speakers include:

Dr Richard Finn (UCLA), Dr. Sara Huvitz (UCLA),
Dr. Mark Pegram (Stanford), Dr. Cliona Rooney (Texas),
Dr Steve Shak (Genomic Health), Dr. Maeve Lowery (TCD),
Dr. Lillian Smyth (MSKCC) , Dr Maurizio Scaltriti (MSKCC),
Prof Lajos Pusztai (Yale), Dr Kevin Curran (MSKCC),

Attendance is free but registration is required.

Register: karen.culhane@ccrt.ie

Website: <http://www.ccrt.ie>

CPD accreditation pending

CHY12210

11TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Thursday, 27th September, Lansdowne Suite, Herbert Park Hotel, Ballsbridge, D4

Registration from 08:30

9:00 – 9:15 Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin

TARGETED THERAPIES

Chair: Prof John Crown

- 9:15 – 9:45 **Overcoming Resistance to HER2 Targeted Therapy**
Dr. Mark Pegram, Department of Medicine, Stanford University
- 9:45 – 10:15 **Title: to be confirmed (Neratinib)**
Dr. Lesley-Ann Martin, Institute of Cancer Research, London
- 10:15–10:45 **Genomic determinants of response to therapy in breast cancer**
Dr. Maurizio Scaltriti, Memorial Sloan Kettering Cancer Center, New York
- 10:45 – 11:00 *Coffee break*
- 11:00 – 11:30 **Dasatinib and HER2-targeted therapy resistance in breast cancer.**
Dr. Denis Collins, National Institute for Cellular Biotechnology, Dublin City University
- 11:30– 12:00 **Title: to be confirmed**
Dr Shane Olwill, VP, Head of Development & Immuno-Oncology, Pieris Pharmaceuticals
- 12:00–12:30 **CDK 4/6 Inhibition in Cancer Medicine: the Next Phase**
Dr. Richard Finn, Assistant Professor of Medicine, Geffen School of Medicine, UCLA
- 12:30- 1:00 **Targeting IGF Signaling in HR+ Breast Cancer with Xentuzumab: an Update**
Dr. Thomas Bogenrieder, University Hospital Grosshadern, Munich & Boehringer-Ingelheim
- 1.00-2.00** *Lunch, Herbert Suite*
- 2:00-2:30 **Ladiratumumab Vedotin: A Clinically Active Molecule with Multiple Potential Mechanisms of Action**
Dr. Norman Barlow, Head of Nonclinical Sciences, Seattle Genetics
- 2:30-3.00 **Targeted therapies for BRCA mutated and triple negative breast cancers**
Dr. Sara Hurvitz, Division of Hematology-Oncology, Geffen School of Medicine, UCLA
- 3:00-3:30 **AKT inhibition in AKT mutant tumors**
Dr. Lillian Smyth, Memorial Sloan Kettering Cancer Centre, New York
- 3.30-3.45** *Coffee break*

TARGETING FAMILIAL CANCERS

Chair: Robert Leonard

- 3:45-4.15 **Exploring the function of genetic variants in the non-coding genomic regions in familial breast cancer**
Dr. Adrian Bracken, Smurfit Institute of Genetics, Trinity College Dublin
- 4:15-4:45 **GWAS-pathway analysis and functional validation of candidate susceptibility genes in pancreatic cancer**
Dr. Naomi Walsh, National Institute for Cellular Biotechnology, Dublin City University
- 4:45-5:15 **Germline mutations in pancreatic cancer – targeting defective DNA repair**
Dr. Maeve Lowery, Professor of Translational Cancer Medicine, Trinity College Dublin

11TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Friday, 28th September, Landsdowne Suite, Herbert Park Hotel, Ballsbridge, D4

Registration from 08:30

9:00 – 9:15 Welcome and Introduction – Prof John Crown, St. Vincent’s University Hospital, Dublin

IMMUNOTHERAPY

Chair: Dr. Mario Sznol

- 9:15 – 9:45 **Title: to be confirmed**
Dr. Mario Sznol, Professor of Medicine, Yale Cancer Centre
- 9:45 – 10:15 **Immunological differences between primary and metastatic breast cancer**
Prof. Lajos Pusztai, Director, Yale Cancer Center Genetics, Genomics and Epigenetics Program
- 10:15 – 10:45 **Title: to be confirmed**
Prof. Giuseppe Gullo, Consultant Medical Oncologist, St. Vincent’s University Hospital, Dublin, Ireland
- 10:45 – 11:00 *Coffee break*
- 11:00-11:30 **Immune contexture in colon cancer**
Prof Jérôme Galon, Laboratory of Integrative Cancer Immunology, INSERM, Paris, France
- 11:30-12:00 **Chimeric Antigen Receptor (CAR) T Cells for Cancer Immunotherapy**
Dr. Kevin Curran, Memorial Sloan Kettering Cancer Centre
- 12:00-12:30 **Improving the expansion and persistence of CAR T-cells for solid tumors**
Dr. Cliona Rooney, Baylor College of Medicine, Houston, Texas
- 12:30 -1:00 **New clinical data supporting the inevitable use of anti-hypoxia-adenosinergic drugs to improve current immunotherapies of cancer.**
Prof. Michail Sitkovsky, Northeastern University, Boston
- 1:00- 2:00 *Lunch, Herbert Suite*

ANGIOGENESIS

Chair: Prof Bob Kerbel

- 2:00-2:30 **Preclinical and clinical update on metronomic chemotherapy: where do we (I) go from here?**
Prof. Robert Kerbel, Sunnybrook Health Science Centre, Toronto
- 2:30-3:00 **Targeting angiogenesis and metabolism in the tumour microenvironment to boost treatment response in GI cancers**
Professor Jacintha O’Sullivan, Professor in Translational Oncology, Trinity Translational Medicine Institute, Dublin
- 3:30-4:00 **Title: to be confirmed (Vessel Co-option angiogenesis)**
Dr. Andrew Reynolds,
- 3:30-3:45 *Coffee break, Herbert Suite*
- 3:45-4:15 **The metastatic switch in the tumor microenvironment following anti cancer therapy**
Dr. Yuval Shaked, Nanotechnology Institute Technion-Israel Institute of Technology
- 4.15-4:45 **Improving immunotherapy using a new RGD-mimetic prodrug that induces vascular promotion**
Dr. Kairbaan Hodivala-Dilke, Barts Cancer Institute, Queen Mary University of London

11TH INTERNATIONAL SYMPOSIUM ON TRANSLATIONAL RESEARCH IN ONCOLOGY



Saturday 29th September, Landsdowne Suite, Herbert Park Hotel, Ballsbridge, D4

Registration from 8:30

PERSONALISED MEDICINE

Chair: Prof John Crown

- 9:00-9:30 **Title: to be confirmed**
Dr. Steve Shak, Chief Scientific Officer, Genomic Health
- 9:30-10:00 **Fast-Tracking Molecular Diagnostics in Oncology**
Prof. William Gallagher, School of Biomolecular and Biomedical Science, University College Dublin
- 10:00-10:30 **Title: to be confirmed**
Dr. Richard Williams, Managing Director and Head of Oncology Programs, WuXi NextCODE
- 10:30-11:00 **UCLA-TORL, A Pipeline for Drug Discovery**
Dr. Neil O'Brien, Assistant Professor, Department of Medicine, UCLA
- 11:00-11:15 Coffee break, Herbert Suite*

DNA DAMAGE REPAIR

Chair: Prof Joe Duffy

- 11:15-11:45 **Mutant p53 as a Therapeutic Target for Cancer Treatment**
Prof. Joe Duffy, St. Vincent's University Hospital, Clinical Research Centre, Dublin
- 11:45-12:15 **COTI-2: preclinical and early clinical results from an orally available small molecule targeting mutant p53**
Dr. Richard Ho, Chief Scientific Officer, Cotinga Pharmaceuticals
- 12:15-12:45 **Development of olaparib in prostate cancer; combinations and patient selection**
Dr. Carrie Adelman, Associate Principal Translational Scientist, AstraZeneca, UK
- 12:45-1:15 **Targeting Non-Homologous End Joining by M3814, a potent and selective inhibitor of DNA dependent protein kinase**
Dr. Frank Zenke, Head of Cellular Pharmacology, Translational Innovation Platform Oncology, Merck
- 1:15-2:00 Lunch, Herbert Suite*
- 2:00-2:30 **Developing Inhibitors Against Rare Oncogenic Kinases**
Michael Craig Cox, Sr Director, Clinical Development & Medical Affairs, Loxo Oncology, Inc.
- 2:30-3:00 **CDK8/19: breast cancer and beyond**
Prof. Igor Roninson, Director, Centre for Targeted Therapies, University of South Carolina
- 3:00-3:30 **Found in Translation: How Preclinical Studies are Guiding Clinical Development of the BCL-2 Inhibitor Venetoclax**
Dr. Joel Levenson, Scientific Director, Oncology Development, AbbVie
- 3:30-3:45 Coffee break, Herbert Suite*

TARGETED THERAPIES

Chair: Dr. Wolfgang Eiermann

- 3:45-4:15 **Sarcoma in the 21st Century: Translating New Targets into Cancer Medicine**
Dr. Gary Schwartz, Colombia Presbyterian University
- 4:15-4:45 **Non-cytotoxic, non-antimitotic effects of eribulin on the tumor immune micro-environment**
Dr. Bruce Littlefield, Scientist and Head, Translational Medicine, Eisai Inc.
- 4:45-5:15 **hSSB1, a novel target for therapy in solid tumours**
Prof Ken O'Byrne, Princess Alexandra Hospital, Queensland University of Technology